nach oben

Die Kardiologie

Erschienen in:

13.02.2017 | Direkte orale Antikoagulanzien | CME

Zustand nach Lungenembolie

verfasst von: PD Dr. M. Lankeit, PD Dr. C. Opitz

Erschienen in: Die Kardiologie | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Patienten nach Lungenembolie sind durch ein hohes Risiko für Rezidive, Blutungen, Folgeerkrankungen und Mortalität gefährdet. Die Abschätzung des Nutzen-Risiko-Verhältnisses einer (verlängerten) Antikoagulation kann durch differenziertere Betrachtung von Risikofaktoren für eine venöse Thromboembolie und Anwendung des VTE-BLEED-Scores zur Abschätzung des Blutungsrisikos optimiert werden. Durch eine Therapie mit nicht-Vitamin‑K abhängigen oralen Antikoagulanzien kann das Blutungsrisiko reduziert werden. Eine strukturierte Nachsorge ermöglicht die Erkennung und Behandlung von Komplikationen und Folgeerkrankungen. Persistierende oder wiederkehrende Dyspnoe und Leistungsminderung sollten immer Anlass zur weiterführenden Diagnostik geben, um das Vorliegen einer chronisch thromboembolischen pulmonalen Hypertonie auszuschließen. Diese seltene Erkrankung ist unbehandelt mit einer schlechten Prognose assoziiert und kann durch eine pulmonale Endarteriektomie kurativ behandelt werden.

Konstantinides SV, Torbicki A, Agnelli G et al (2014) 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 35:3033–3069 (3069a–3069k)CrossRefPubMed

Konstantinides S, Bauersachs J, Mayer E, Hambrecht R (2015) Kommentar zur 2014-ESC Leitlinie zum Management der akuten Lungenembolie. Kardiologe 9:289–294CrossRef

Prandoni P, Noventa F, Ghirarduzzi A et al (2007) The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 92:199–205CrossRefPubMed

Kearon C, Gent M, Hirsh J et al (1999) A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340:901–907CrossRefPubMed

Agnelli G, Prandoni P, Becattini C et al (2003) Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 139:19–25CrossRefPubMed

Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing GJ, Kyrle PA (2016) Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost 14:1480–1483CrossRefPubMed

Couturaud F, Sanchez O, Pernod G et al (2015) Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: the PADIS-PE randomized clinical trial. JAMA 314:31–40CrossRefPubMed

Klok FA, Kooiman J, Huisman MV, Konstantinides S, Lankeit M (2015) Predicting anticoagulant-related bleeding in patients with venous thromboembolism: a clinically oriented review. Eur Respir J 45:201–210CrossRefPubMed

Kirchhof P, Benussi S, Kotecha D et al (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893–2962CrossRefPubMed

10.

Klok FA, Niemann C, Dellas C, Hasenfuß G, Konstantinides S, Lankeit M (2016) Performance of five different bleeding-prediction scores in patients with acute pulmonary embolism. J Thromb Thrombolysis 41:312–320CrossRefPubMed

11.

Riva N, Bellesini M, Di Minno MN et al (2015) Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism. A multicentre retrospective cohort study. Thromb Haemost 112:511–521CrossRef

12.

Klok FA, Hösel V, Clemens A et al (2016) Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. Eur Respir J 48:1369–1376CrossRefPubMed

13.

van Es N, Coppens M, Schulman S, Middeldorp S, Buller HR (2014) Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 124:1968–1975CrossRefPubMed

14.

Ageno W, Mantovani LG, Haas S et al (2016) Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol 3:e12–e21CrossRefPubMed

15.

Beyer-Westendorf J, Förster K, Pannach S et al (2014) Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 124:955–962CrossRefPubMedCentralPubMed

16.

Kearon C, Akl EA, Ornelas J et al (2016) Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 149:315–352CrossRefPubMed

17.

Gómez-Outes A, Lecumberri R, Suárez-Gea ML, Terleira-Fernández AI, Monreal M, Vargas-Castrillón E (2015) Case fatality rates of recurrent thromboembolism and bleeding in patients receiving direct oral anticoagulants for the initial and extended treatment of venous thromboembolism: A systematic review. J Cardiovasc Pharmacol Ther 20:490–500CrossRefPubMed

18.

Simes J, Becattini C, Agnelli G et al (2014) Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation 130:1062–1071CrossRefPubMed

19.

Faller N, Limacher A, Méan M et al (2016) Predictors and causes of long-term mortality in elderly patients with acute venous thromboembolism: A prospective cohort study. Am J Med. doi:10.1016/j.amjmed.2016.09.008)PubMed

20.

Maggioni AP, Dahlström U, Filippatos G et al (2013) EURobservational research programme: regional differences and 1‑year follow-up results of the heart failure pilot survey (ESC-HF pilot). Eur J Heart Fail 15:808–817CrossRefPubMed

21.

Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 37:2129–2200CrossRefPubMed

22.

van Es J, Douma RA, Kamphuisen PW et al (2013) Clot resolution after 3 weeks of anticoagulant treatment for pulmonary embolism: comparison of computed tomography and perfusion scintigraphy. J Thromb Haemost 11:679–685CrossRefPubMed

23.

Sanchez O, Helley D, Couchon S et al (2010) Perfusion defects after pulmonary embolism: risk factors and clinical significance. J Thromb Haemost 8:1248–1255CrossRefPubMed

24.

Cosmi B, Nijkeuter M, Valentino M, Huisman MV, Barozzi L, Palareti G (2011) Residual emboli on lung perfusion scan or multidetector computed tomography after a first episode of acute pulmonary embolism. Intern Emerg Med 6:521–528CrossRefPubMed

25.

Stevinson BG, Hernandez-Nino J, Rose G, Kline JA (2007) Echocardiographic and functional cardiopulmonary problems 6 months after first-time pulmonary embolism in previously healthy patients. Eur Heart J 28:2517–2524CrossRefPubMed

26.

Klok FA, van der Hulle T, den Exter PL, Lankeit M, Huisman MV, Konstantinides S (2014) The post-PE syndrome: a new concept for chronic complications of pulmonary embolism. Blood Rev 28:221–226CrossRefPubMed

27.

Kahn SR, Hirsch AM, Akaberi A et al (2016) Functional and exercise limitations after a first episode of pulmonary embolism: results of the ELOPE prospective cohort study. Chest. doi:10.1016/j.chest.2016.11.030)PubMed

28.

Held M, Hesse A, Gött F et al (2014) A symptom-related monitoring program following pulmonary embolism for the early detection of CTEPH: a prospective observational registry study. BMC Pulm Med 14:141CrossRefPubMedCentralPubMed

29.

Wilkens H, Konstantinides S, Lang I et al (2016) Chronic thromboembolic pulmonary hypertension: Recommendations of the Cologne Consensus Conference 2016. Dtsch Med Wochenschr 141:S62–S69CrossRefPubMed

30.

Konstantinides SV, Barco S, Rosenkranz S et al (2016) Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study. J Thromb Thrombolysis 42:600–609CrossRefPubMedCentralPubMed

31.

Galiè N, Humbert M, Vachiery JL et al (2016) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 37:67–119CrossRefPubMed

32.

Ehlken N, Lichtblau M, Klose H et al (2016) Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial. Eur Heart J 37:35–44CrossRefPubMed

33.

Frey PM, Méan M, Limacher A et al (2015) Quality of life after pulmonary embolism: Prospective validation of the German version of the PEmb-QoL questionnaire. Thromb Res 135:1087–1092CrossRefPubMed

34.

Lang IM, Pesavento R, Bonderman D, Yuan JX (2013) Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J 41:462–468CrossRefPubMed

35.

Pepke-Zaba J, Delcroix M, Lang I et al (2011) Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 124:1973–1981CrossRefPubMed

36.

Guérin L, Couturaud F, Parent F et al (2014) Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism. Thromb Haemost 112:598–605CrossRefPubMed

37.

Held M, Grün M, Holl R et al (2014) Chronic thromboembolic pulmonary hypertension: Time delay from onset of symtoms to diagnosis and clinical condition at diagnosis. Dtsch Med Wochenschr 139:1647–1652CrossRefPubMed

38.

Klok FA, Dzikowska-Diduch O, Kostrubiec M et al (2016) Derivation of a clinical prediction score for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. J Thromb Haemost 14:121–128CrossRefPubMed

39.

Klok FA, Tesche C, Rappold L et al (2016) External validation of a simple non-invasive algorithm to rule out chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Thromb Res 135:796–801CrossRef

40.

Heidbuchel H, Verhamme P, Alings M et al (2015) Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17:1467–1507CrossRefPubMed

41.

Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J (2016) Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis 41:206–232CrossRefPubMedCentralPubMed

Titel: Zustand nach Lungenembolie
verfasst von: PD Dr. M. Lankeit
PD Dr. C. Opitz
Publikationsdatum: 13.02.2017
Verlag: Springer Medizin
Schlagwörter: Direkte orale Antikoagulanzien
Pulmonale Hypertonie
Direkte orale Antikoagulanzien
Endarteriektomie
Pulmonale Hypertonie
Pulmonale Hypertonie
Pulmonale Hypertonie
Erschienen in: Die Kardiologie / Ausgabe 2/2017
Print ISSN: 2731-7129
Elektronische ISSN: 2731-7137
DOI: https://doi.org/10.1007/s12181-017-0126-4

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Erweiterung einer venoarteriellen (VA) ECMO auf eine venovenoarterielle (VVA) ECMO bei schwerem Harlekinsyndrom

MR-Untersuchungen bei Patienten mit Herzschrittmachern und implantierbaren Kardioverter‑Defibrillatoren

Klappenerhalt vor Klappenersatz – gilt das immer?

Bypassoperation bei Mehrgefäß‑KHK

Update Cardio

„Left ventricular noncompaction“